GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Gross Profit

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Gross Profit : €-2.67 Mil (TTM As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings Gross Profit?

Oxford Cannabinoid Technologies Holdings's gross profit for the six months ended in Oct. 2023 was €-1.35 Mil. Oxford Cannabinoid Technologies Holdings's gross profit for the trailing twelve months (TTM) ended in Oct. 2023 was €-2.67 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Oxford Cannabinoid Technologies Holdings's gross profit for the six months ended in Oct. 2023 was €-1.35 Mil. Oxford Cannabinoid Technologies Holdings's Revenue for the six months ended in Oct. 2023 was €0.00 Mil. Therefore, Oxford Cannabinoid Technologies Holdings's Gross Margin % for the quarter that ended in Oct. 2023 was %.

Oxford Cannabinoid Technologies Holdings had a gross margin of % for the quarter that ended in Oct. 2023 => No sustainable competitive advantage


Oxford Cannabinoid Technologies Holdings Gross Profit Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Gross Profit Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Gross Profit
- -1.47 -0.92 -0.52 -4.89

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Gross Profit Get a 7-Day Free Trial Premium Member Only -0.34 -1.10 -3.62 -1.31 -1.35

Competitive Comparison of Oxford Cannabinoid Technologies Holdings's Gross Profit

For the Biotechnology subindustry, Oxford Cannabinoid Technologies Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Cannabinoid Technologies Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Cannabinoid Technologies Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Oxford Cannabinoid Technologies Holdings's Gross Profit falls into.



Oxford Cannabinoid Technologies Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Oxford Cannabinoid Technologies Holdings's Gross Profit for the fiscal year that ended in Apr. 2023 is calculated as

Gross Profit (A: Apr. 2023 )=Revenue - Cost of Goods Sold
=0 - 4.888
=-4.89

Oxford Cannabinoid Technologies Holdings's Gross Profit for the quarter that ended in Oct. 2023 is calculated as

Gross Profit (Q: Oct. 2023 )=Revenue - Cost of Goods Sold
=0 - 1.352
=-1.35

Gross Profit for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.67 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Oxford Cannabinoid Technologies Holdings's Gross Margin % for the quarter that ended in Oct. 2023 is calculated as

Gross Margin % (Q: Oct. 2023 )=Gross Profit (Q: Oct. 2023 ) / Revenue (Q: Oct. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=-1.35 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Oxford Cannabinoid Technologies Holdings  (FRA:0CB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Oxford Cannabinoid Technologies Holdings had a gross margin of % for the quarter that ended in Oct. 2023 => No sustainable competitive advantage


Oxford Cannabinoid Technologies Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines